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Abstract
Individual Treatment Effect (ITE) estimation is an extensively researched problem, with
applications in various domains. We model the case where there is heterogeneous non-compliance
to a randomly assigned treatment, a typical situation in health (because of non-compliance to
prescription) or digital advertising (because of competition and ad blockers for instance). The lower
the compliance, the more the effect of treatment prescription − or individual prescription effect
(IPE) − signal fades away and becomes hard to capture. We propose a new approach to estimate
IPE that takes advantage of observed compliance information to prevent signal fading. Using the
Structural Causal Model framework and do-calculus, we define a general mediated causal effect
setting under which our proposed estimator soundly recovers the IPE, and study its asymptotic
variance. Finally, we conduct extensive experiments on both synthetic and real-world datasets that
highlight the benefit of the approach, which consistently improves state-of-the-art in low compliance
settings.
1 Introduction
Individual Treatment Effect (ITE) estimation is an important task in various applications such as
healthcare Foster et al. (2011), online advertising Diemert et al. (2018) and socio-economics Xie et al.
(2012). As it is often the case in practice, we assume that we cannot directly control the treatment
intake but only the treatment prescription (or assignment): we therefore focus on the Individual
Prescription Effect (IPE), which designates the effect of the treatment prescription T on the outcome
Y , conditionally to context X (c.f. Equation (1), assuming randomized treatment prescription).
IPE(x) = E[Y |X = x, T = 1]− E[Y |X = x, T = 0] (1)
We also assume that we observe the treatment intake (or equivalently, the compliance to prescription),
which we denote M since it acts as a mediator of the causal effect of T on Y . The effect of M on Y
will henceforth be referred to as ITE.
Table 1 illustrates various settings in which non-compliance to treatment prescription may occur
(Gordon et al., 2019; Jin et al., 2008; Parker, 2000). This happens for instance when individuals have
the choice not to abide by the prescription or if there exists conflicting interests. Of course one can
choose to focus the study on actually treated individuals only (ITE). But from a decision making point
of view it often makes sense to consider that future treatment decisions need to take into account the
possibility of non-compliance so as to accurately predict future expected outcomes. For example a
policy maker would want to take into account that not all individuals would abide by the new policy
(as can be estimated from a pilot study) to predict the expected impact of a roll-out of said policy.
Now we argue that IPE estimation can be hampered by non-compliance. Firstly note that individuals
who did not receive the treatment contribute only noise to the default IPE estimator as their observed
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Table 1: Examples of covariates (X), outcome (Y ), treatment prescription (T ), reason for not abiding
to treatment (R) and evidence of treatment acceptance (M)
Var. Medicine Online adv. Job training
X patient info purchase history schooling
T drug prescription bid placement training offer
R reluctance competition disease
M drug intake ad displayed training done
Y recovery sale/visit employment
outcome is not effectively influenced. Therefore the variance of the estimator increases when the
compliance level decreases. A classical move in statistics would be to build a stratified estimator on the
treatment variable. But we will see in Section 3 that even when observing data from a randomized
experiment one needs additional assumptions to build a consistent estimator that recovers the causal
effect of T on Y .
Besides, in the literature ITE models (also called uplift models in marketing literature) are often
considered as prescriptive tools. Indeed, treatment effect predictions are used in order to target
treatment to individuals for which it is the most beneficial (Devriendt et al., 2018; Radcliffe & Surry,
2011). This calls for an evaluation metric that measures by how much the average treatment effect
would have been improved had the treatment been targeted not by a random instrument, but by ITE
predictions instead. For that purpose (Rzepakowski & Jaroszewicz, 2012, 2010; Radcliffe & Surry, 2011)
have proposed the Area Under the Uplift Curve (AUUC) metric that sums the benefits over individuals
ranked by predictions. An interesting property of this metric is that it can be used on real data for
which we observe a given individual in either treated or untreated conditions but never both.
Confronted with the challenges of i) learning IPE models in conditions of (possibly high) non-
compliance and ii) evaluating them as prescriptive tools we propose to pose the problem in the setting
of causal inference and derive an IPE estimator that takes advantage of observed compliance. Our
main contributions are as follows.
1. Formalization of IPE estimation in a setting of observed compliance described using structural
causal models, which extends to more general cases of mediated causal effect estimation (Section
3)
2. Proposition of a meta-estimator (in which can be plugged any ITE estimator) improving robustness
of classical causal effect estimators to (high) non-compliance settings, proof of consistency
(Section 4.1) and asymptotic variance properties (Section 4.2)
3. Thorough empirical evaluation of this meta-estimator on synthetic and real world datasets
(Section 5)
2 Related works
We review three main domains that are concerned with research questions similar to our work: ITE
modeling, non compliance in causal inference and evaluation metrics for ITE modeling.
First, we note that ITE models are a pervasive concept in different research fields such as marketing
- under the name uplift models Radcliffe & Surry (2011), statistics - as conditional average treatment
effect estimators Ku¨nzel et al. (2019) or econometrics - heterogeneous treatment effect models (Jacob
et al., 2019; Wager & Athey, 2018). A simple yet highly scalable approach consists in learning a
regression of Y on X separately in both treatment (T = 1) and control (T = 0) populations and
return the difference, known as T-learner Ku¨nzel et al. (2019) or “Two Models” Radcliffe & Surry
(2011). A variation of this approach with larger model capacity have been proposed through a shared
representation (SDR) for the treatment and control group in Betlei et al. (2018). Also, a prolific series
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of work exists on adapting decision trees and random forests to the causal inference framework Athey
& Imbens (2016); Wager & Athey (2018); Athey et al. (2019). Further in the same vein and building on
work done on double machine learning by Chernozhukov et al. (2018), Oprescu et al. (2019) generalize
the idea of causal forests, allowing for high-dimensional confounding. Finally, another recent trend is to
study theoretical limits in ITE estimation and especially generalization bounds Shalit et al. (2017);
Alaa & Van Der Schaar (2018).
Then regarding the concept of non compliance, many algorithms have been studied in order to
recover (individual) causal effect in non-compliance settings, however to our knowledge, works tackling
this problem focus solely on effect of the treatment intake M − and not the treatment prescription
T − on the outcome Y (Gordon et al., 2019). In that context, the effect of T on Y is sometimes
studied in an instrumental variable framework to recover the effect of M on Y Imbens & Angrist
(1994); Syrgkanis et al. (2019). We focus in estimating the effect of the treatment prescription T
on the variable Y , taking advantage of the observed treatment intake M , in the spirit of individual
intention-to-treat (ITT) analysis (Montori & Guyatt, 2001; Gupta, 2011). The idea of taking advantage
of a mediation variable to recover individual treatment effect has been explored notably by Hill et al.
(2015), however the associated assumptions (M and Y are unconfounded) are more restrictive than the
ones we propose, as we do not require the binary mediation variable M (representing the treatment
intake) to be unconfounded with Y . We do however assume that it satisfies a strong monotonicity
assumption with respect to the binary variable T , i.e. T = 0⇒M = 0: an analogous assumption is
referred to as one-sided non-compliance by Gordon et al. (2019).
Similar monotonicity assumptions are typically made in causal inference works but concern the causal
effect: the outcome Y is assumed to be monotonous with respect to the treatment T Kallus (2019);
Oberst & Sontag (2019).
Finally, many research works validate their approach using synthetic data, in which a pointwise
error measure named Precision Estimation of Heterogeneous Effect (PEHE) Shalit et al. (2017) can be
computed. However in real world cases, the fundamental problem of causal inference states that the
ground truth of individual treatment effect cannot be observed (since an individual is either treated
or untreated but never both at the same time), preventing to use such metrics beyond simulation
studies. Since our main motivation is to determine which individuals are good candidates for treatment
prescription, we choose to evaluate the performance of our estimators on real data using the AUUC,
which evaluates the ranking of individuals implied by corresponding ITE or IPEpredictions. One can
view the resulting measure as a prediction of the expected benefit of assigning treatment according
to the model prediction instead of a random uniform prescription. Overall AUUC has been used in
recent years in machine learning research to evaluate baseline ITE models vs SDR Diemert et al. (2018),
flavors of Support Vector Machines for ITE estimation Kuusisto et al. (2014) or direct treatment policy
optimization Yamane et al. (2018). For completeness a variant normalized by the ranking of an oracle
model exists also under the name Qini coefficient Radcliffe & Surry (2011).
3 Framework
We briefly recall causality notions used throughout the paper, such as structural causal model, causal
graph, intervention and valid adjustment set first introduced by Pearl (2009), and presented in Peters
et al. (2017).
Definition 1 Structural Causal Model (SCM) A SCM of variables X = {X1, . . . , Xd} is an object
C := (S,PN) where:
(1) S is a set of d structural assignments Xi = fi(PAi, Ni), with the fi’s deterministic functions and
PAi the set of parents (direct causes) of Xi.
(2) PN = PN1,...,Nd is a joint distribution over the noise variables {Ni}1≤d, which we require to be
jointly independent.
As shown in Chapter 6 of Peters et al. (2017), a SCM C induces a unique causal graph GC, defined
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as the directed acyclic graph (DAG) obtained by creating a vertex for each Xi and drawing directed
edges from each PAi to Xi, thus justifying the term ‘parents’ for the sets PAi, and a unique entailed
distribution PC over variables X1, . . . , Xd such that for each i, Xi = fi(PAi, Ni) in distribution.
A SCM can be used to define interventional distributions. A (hard) intervention do(Xi = xi) is
a forced assignment of variable Xi to the value xi, which implies a change in the distribution of the
variables X1, . . . , Xd. Formally, an intervention do(Xi = xi) is equivalent to modifying C in two ways:
(1) change the structural assignment Xi = fi(Xi,PAi) to Xi = xi in S and (2) replace Xi by xi in all
other structural assignments implying Xi in S.
We will denote by PC;do(Xi:=xi) the probability distribution entailed by the SCM C under the intervention
do(Xi := xi).
Let Xi, Xj ∈ X, Z ⊆ X\{Xi, Xj} is called a valid adjustment set (VAS) for the ordered pair
(Xi, Xj), if
PC;do(Xi)(Xj) =
∑
z
PC(Xj |Xi, z)PC(z),
where the sum is over the range of Z.
Notations. For sake of compactness, we use the following notations for any binary variable W
and multi-dimensional variable X: P(W ) , P(W = 1), P(W ) , P(W = 0), P(x) , P(X = x),
PC;do(W )(.) , PC;do(W :=1)(.).
3.1 Non-compliance setting
The setting of non-compliance we consider in this work is entirely defined by a SCM of variables
X,T,M, Y, U for which example values where proposed in Table 1: X, belonging to a multi-dimensional
space X , contains the individual’s descriptive features (by simplicity, we will confuse the individual
and their features, referring for example to ‘an individual x’), T is the binary treatment prescription
variable, M is the binary mediation variable, corresponding to the treatment acceptation, i.e. the fact
that the individual did not interfere with their treatment prescription, Y is the binary outcome variable,
U represents (allowed) unobserved confounders between X and Y .
In what follows, we define the structural causal model C = (S,PN), which is henceforth assumed to
represent the causal mechanisms underlying the variables of interest in our work.
S is defined in Equations 2:
T = N˜T
U = NU
X = fX(U,NX)
M = fM (X,NM )× T
Y = fY (X,M,U,NY ).
(2)
PN satisfies the following mild conditions: NU , NX , NM , NY are noise consistent with variables defini-
tions, and N˜T is distributed according to a Bernoulli distribution with parameter p = PC(T ), consistent
with a randomized controlled experiment setting.
The associated causal graph GC is given in Figure 1
T M Y
X U
Figure 1: Causal graph GC induced by the SCM C
In the next proposition, we list four assumptions implied by C about the variables of interest.
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Proposition 1 The SCM C defined in Equations 2 implies the following assumptions on variables T ,
M , Y and X:
(Randomized treatment) T ⊥⊥ X
(Exclusive treatment effect) T ⊥⊥ Y | {X,M}
(One-sided non-compliance) T = 0⇒M = 0
(Valid covariate adjustment) {X} is a VAS for (M,Y )
(3)
The fact that C implies the randomized treatment and Exclusive treatment effect assumptions
relies on the Markov property of the causal graph GC and the notion of d-separation. The One-sided
non-compliance is straightforwardly implied by the structural assignment of M given in Equations 2,
while the valid covariate adjustment assumption relies on the back-door criterion (Pearl, 2009; Peters
et al., 2017). The complete proof of Proposition 1, including definitions of the associated notions, is
given in appendix.
Detailed review of assumptions. We now review in details the assumptions presented in
Equation 3 and their connections to applications and usual theoretical settings.
- Randomized treatment translates the fact that each individual is randomly allocated to a treatment
prescription (T = 1) or a control (T = 0) group, allowing us to infer the causal effect of T on Y without
worrying about confounding bias. This is a typical situation in experiments such as A/B tests or
randomized controlled clinical trials.
- Exclusive treatment effect captures the fact that the prescription to treatment T has an effect on the
outcome Y only if the treatment is actually taken M = 1. More generally, this assumption translates
the fact that the effect of T on Y is fully mediated by M . This is typically assumed to be the case in
online advertising, in which case T is the allocation to treatment or control conditions and M is the
actual exposure to advertisement Gordon et al. (2019).
- One-sided non-compliance (Gordon et al., 2019) states that T = 0 =⇒ M = 0, but that T = 1 6=⇒
M = 1. In other words, treatment is only taken (M = 1) in cases where it was originally assigned
(T = 1). This assumption is typically satisfied in the instrumental variable setting where T plays the
role of the instrument for the estimation of the effect of M on Y (Syrgkanis et al., 2019), the main
difference with our work resides in the fact that we are interested in the effect of T on Y , IPE.
- Valid covariate adjustment : there is no confounder, outside of X, for the effect of M on Y . This
assumption is classically made in ITE estimation works (Alaa & Van Der Schaar, 2018, 2019) and
is sometimes referred to as ignorability Shalit et al. (2017). Under the potential outcome framework
Rubin (2005), this assumption is equivalent to Y (M = 1), Y (M = 0) ⊥⊥ M |X. Strong ignorability
(where we additionally assume that 0 < P(M |x) < 1 for all x) has been proven to be sufficient to
recover the individual causal effect of M on Y (Imbens & Wooldridge, 2009; Pearl, 2017).
3.2 IPE in presence of non-compliance
Notations. For all x ∈ X , we define the individual prescription effect τ IPE(x), treatment effect if
treated τ ITE(x), as well as the individual compliance γ(x) probability (that we henceforth refer to as
individual compliance for clarity) as follows:
τ IPE(x) = PC;do(T )(Y |x)− PC;do(T )(Y |x),
τ ITE(x) = PC;do(M)(Y |x)− PC;do(M)(Y |x),
γ(x) = PC;do(T )(M |x).
(4)
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We also define the relative ITE β(x) and relative IPE α(x) as:
α(x) =
PC(Y |T, x)− PC(Y |T , x)
PC(Y |T , x)
β(x) =
PC(Y |M,x)− PC(Y |M,x)
PC(Y |M,x) .
The proposed method exploits the mediation variable M , i.e. the treatment acceptation, by splitting
the treatment to outcome path into a product of two subpaths, both with a higher signal-to-noise ratio.
In particular, under C, we can integrate M into the PC;do(T )(Y |x) expression as presented in the next
lemma.
Lemma 1 Assuming C, and for any x ∈ X , the positive outcome probability under treatment,
PC;do(T )(Y |x), can be written as follows:
PC;do(T )(Y |x) = PC(Y |x,M) + PC(M |x, T )
(
PC(Y |x,M)− PC(Y |x,M)
)
. (5)
The proof of Lemma 1 is fully detailed on appendix. It relies on valid covariate adjustment, randomized
treatment, and exclusive mediation assumptions, that we have proven to be implied by C in Proposition 1.
The different terms of Equation (5) have an intuitive interpretation, indeed:
PC(M |x, T ) = γ(x) is the compliance of individual x, i.e. the probability an individual with features
x who is assigned to treatment accepts this treatment. PC(Y |x,M) − PC(Y |x,M) = τ ITE(x) is the
ITE of user x. PC(Y |x,M), the individual probability of positive outcome of an individual x given
they did not receive treatment. It is referred to as the organic probability of positive outcome.
In a nutshell, the Lemma 1 decomposes the positive outcome probability under treatment of a given
individual as the sum of the organic positive outcome probability and the product of individual
compliance and individual treatment effect if treated.
In Proposition 2, we present a result linking the IPE , the ITE and the individual compliance:
Proposition 2 Assuming C, the IPE decomposes as follows:
τ IPE(x) = τ ITE(x)γ(x) (6)
The proof of Proposition 2 is fully detailed in appendix. It relies on the identity PC;do(T )(Y |x) =
PC(Y |x,M), which holds under C thanks to the exclusive mediation and strong mediation monotonicity
assumptions.
In intuitive terms, the individual prescription effect (IPE) is expressed as the individual treatment
effect (ITE) multiplied by the individual compliance probability.
4 Proposed Approach
4.1 Definition and basic properties
The expression proven in Proposition 2 calls for a novel way to estimate individual treatment effect, by
first estimating separately both factors τ ITE(x) and γ(x), then multiplying these estimators to form a
compliance aware individual intention-to-treat effect (C-IPE) estimator.
Formally, let τˆ ITE be an estimator of τ ITE , let γˆ be an estimator of γ. We then define the associated
C-IPE estimator τˆC−IPE , for any x, as:
τˆC−IPE(x) = τˆ ITE(x)γˆ(x). (7)
In practice, τˆ ITE may be obtained using any individual treatment effect estimator. Indeed, under
C, the individual causal effect of M on Y given X is recoverable since {X} is a valid adjustment set for
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(M,Y ) as explained in Section 3. C-IPE is not an estimator per say, but rather a meta-estimator: a
black-box in which any classical ITE and compliance estimators can be plugged-in.
Assuming that x, τˆ ITE(x) and γˆ(x) are consistent estimators of resp. τ ITE(x) and γ(x), Proposi-
tion 2 then ensures that τˆC−IPE(x) is a consistent estimator of τ IPE(x).
4.2 Asymptotic variance properties
Thanks to its expression as a function of a ITE estimator, the C-IPE estimator focuses on the individuals
who actually accepted treatment, who we know to be the only individuals contributing to the IPE signal
(Exclusive treatment effect assumption in Equation 3). We therefore expect the C-IPE estimator to have
lower variance than an IPE estimator which does not exploit the observable compliance. Comparing a
C-IPE and an IPE estimator is all the more fair than we use an analogous version of the ITE estimator
for the ITE estimator the C-IPE estimator is built on, which we know to be feasible thanks to the
valid covariate adjustment assumption. We refer to this approach as symmetrically learning algorithms
comparison, and use it to conduct our experiments in Section 5.
In the following proposition, we compare the asymptotic variance of estimators τˆC−IPE and τˆ IPE in
the following simple yet realistic setting:
Single-stratum setting. We focus on the IPE estimation for a single value x0 of X, for which
we assume to observe n i.i.d. samples {(x0, Ti,Mi, Yi)}1≤i≤n. In practice, this generalises to any
stratum S ⊂ X containing x0 for which the adjustment set formula is valid, i.e. if the variable
X ′ , x0IX∈S +XIX/∈S defines a valid adjustment set for (M,Y ).
Notations. Consistently with notations presented in Equations 4, α(x0), β(x0) refer respectively
to the relative IPE and relative ITE in stratum {X = x0} (and are assumed to be positive in this
illustrative setting), and we denote γˆ(x0), τˆ
IPE(x0) and τˆ
ITE(x0) respectively the maximum-likelihood
estimator (MLE) of γ(x0), and the MLE-based two-model estimators (difference of two MLE estimators)
of τ IPE(x0) and τ
ITE(x0). We define the associated C-IPE estimator as τˆ
C−IPE(x0) , γˆ(x0)τˆ ITE(x0).
Lastly, we denote p1(x0) = PC(Y |T, x0).
In the following Proposition, we present an asymptotic bound for the ratio of the standard deviation
(sd) of C-IPE and IPE estimators.
Proposition 3 Under C defined in Section 3.1 with PC(T ) = 12 , assuming we observe n i.i.d. samples
in stratum {X = x0}, we have:
lim
n→∞
sd(τˆC−IPE)
sd(τˆ IPE)
≤
√(
2(1 + β)
(1− p1)(2 + α)
)
γ (8)
where we dropped the reference to x0 for clarity.
This theoretical bound shows that the ratio of standard deviations of C-IPE and IPE estimators is
smaller as the compliance factor γ(x0) decreases. However, additional assumptions need to be made
about β(x0) and p1(x0) in order to recover an informative bound in practice.
In real-world datasets presented in Section 5, we consistently observe βˆ(x) ≤ 12 and pˆ1(x) ≤ 0.05,
where the estimators correspond to logistic regression models fined-tuned following the protocol described
in Section 5. Under such assumptions on the orders of magnitude of β(x0) and p1(x0), we can derive a
useful-in-practice bound, as presented in the following remark.
Remark 1 If we additionally assume β(x0) ≤ 12, and p1(x0) ≤ 0.05 we have:
lim
n→∞
sd(τˆC−IPE)
sd(τˆ IPE)
≤ 4√γ. (9)
This bound is derived from loose upper-bounds on β(x0) and p1 and is only presented for illustrative
purposes. It is however still informative in case of low compliance probability (low γ(x0)). For instance,
with γ(x0) ≤ 10−2, Equation 9 reveals that the asymptotic standard deviation of τˆC−IPE is more than
twice smaller than the one of τˆ IPE .
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5 Experiments
To qualify the performance of the C-IPE estimator, we study its benefits in a variety of settings. Firstly
we study its properties on simulation-based studies, hereafter denoted by ‘Synthetic Datasets’, for
which i) the IPE ground truth is known ii) the level of compliance can be controlled and iii) we can
appreciate performance with respect to an Oracle. Moreover we apply our approach to transform
baseline IPE estimators and compare their performance on real-world, large scale datasets, for which
we shall recover the AUUC. The first one is an open dataset from Criteo, named ‘CRITEO-UPLIFT1
Dataset’1. Finally we have privileged access on two other private datasets, designated by ‘Private
datasets’.
In each experiment we take care of comparing symmetrically learning algorithms for which we
provide or not the C-IPE estimator decomposition so as to highlight corresponding benefits or drawbacks.
To simplify experiments we chose two base models: Two Models (2M) and SDR as they easily scale to
large datasets and have been found competitive in prior studies Betlei et al. (2018). For reproducibility
sake we have implemented models using Scikit-Learn Python library Pedregosa et al. (2011) (code
provided as supplementary). All experiments were run on a machine with 48 CPUs (Intel(R) Xeon(R)
Gold 6146 CPU @ 3.20GHz), with 2 Threads per core, and 500Go of RAM. Finally, we note that the
state of the art is always evolving and improving. We did not use the most advanced models because
we do not aim at outperforming them. Instead, we claim that the C-IPE estimator can improve any
IPE estimator (while keeping the same individual treatment effect model) in the case of low observable
compliance.
5.1 Datasets
Synthetic Datasets
We define a simulation setting in which X = {0, 1}10, N = 2.106. The response is generated according
to
Y ∼ Bern (p0 (1 + TMβ(x))) , (10)
where T ∼ Bern(0.5), M ∼ Bern(γ(x)), and p0 = PC(Y |M,x) = 0.1, using notations from
Equations 4. This procedure allows for varying γ(x) and β(x) to simulate different levels of compliance
and relative ITE, respectively.
CRITEO-UPLIFT1 Dataset
We use the CRITEO-UPLIFT1 dataset where data were collected using a randomized trial, from an
advertising application. Key statistics for this dataset are summarized in Table 2 and 3. Notably,
average treatment prescription E[T ] ≈ .85 indicates that only about 15% of users where assigned to
the control group (without any advertisement). The advertisers participated in online ad auctions for
the rest of the population. Among the users that advertisers tried to expose (T = 1), only 3.65% were
actually exposed, which is an extremely low compliance level, expected to highlight C-IPE estimator
benefits. Effective exposure to ads embodies the M variable in this setup. Treatment prescription and
compliance rates are illustrated on Figure 2. The outcome of interest Y is the variable ‘user visiting
the advertiser website’, and its mean is more than 10x higher given actual exposure (M = 1) versus
non-exposure (M = 0).
Private Datasets
We have access to two private datasets of 90M instances, which contain binary treatment and outcome,
and a suitable variable that embodies an observable compliance. They have a higher compliance γ (7.8%
and 10.4%), higher number of features (48) and similar signal strength than the CRITEO-UPLIFT1
1http://cail.criteo.com/criteo-uplift-prediction-dataset/
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Table 2: Distribution of users effectively treated (M = 1) and visits (Y = 1) on CRITEO-UPLIFT1
split on treatment groups
treatment (T ) exposure (M) outcome (Y )
0 (2’096’236) - 3.82% (79’986)
1 (12’161’477) 3.65% (444’384) 4.93% (599’170)
Table 3: Repartition of visits (Y = 1) on CRITEO-UPLIFT1 split on exposure groups
exposure (M) outcome (Y )
0 (13’813’329) 3.58% (495’003)
1 (444’384) 41.4% (184’153)
Figure 2: The visit users repartition is mainly influenced by the mediation variable M on the CRITEO-
UPLIFT1 dataset
dataset. The purpose of extending the study to these datasets is to verify the relationship between
compliance level and performance, predicted by the theoretical study in Section 4.2. The corresponding
data has been collected in the same geographical location, during two separate time periods).
5.2 Experiments
A common procedure for all experiments is to select hyperparameters (regularization norm and strength)
of models using internal cross validation on the training set. For the C-IPE estimators we recall that an
additional probabilistic model of the compliance γˆ(x) is required. For all experiments it is learned on
the training data as a logistic regression. Hyperparameters are selected by internal cross-validation on
the training set by ranking by log-likelihood (LLH) as the model is supposed to predict a probability.
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Compliance Sensitivity Experiment (Simulation)
The goal is to highlight how the compliance level γ influences the performance of both the traditional
IPE estimator and C-IPE estimator. For this purpose we vary γ ∈ [10−4; .99] and generate synthetic
datasets as described in Section 5.1 with a different value β (in {−1, 0, 1, 2, 3, 4, 5, 6, 7, 8}) for each of
the 10 contexts. We report the PEHE metric for both estimators and estimate variance by repeating
experiment with 51 random test/train splits. Recall that PEHE is the squared difference between the
IPE ground truth and the prediction of the model.
0.990.50.10.050.010.001
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1
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·10−3
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√ P
E
H
E
IPE2M
C− IPE2M
Figure 3: Compliance Sensitivity (Simulation study). PEHE (lower is better) of IPE vs C-
IPE models at varying compliance level γ. Solid line represents the median, and dashed line
represents 5% and 95% of confidence intervals. , and : compliance level γ for resp.
CRITEO-UPLIFT1 and private datasets 1 & 2. The x-axis has a simlog scale.
We observe on Figure 3 that the C-IPE estimator significantly outperforms the IPE estimator when
the level of compliance is low (low γ) and has similar performance to baseline IPE when there is full
compliance (γ close to 1). This shows that our post-mediation approach significantly reduces the noises
due to non-compliance and can learn a smaller signal. This is true in particular for compliance levels γ
in the range that is observed on real datasets.
Baseline Experiment (Simulation)
For the synthetic dataset, the goal is to simulate a realistic scenario where there exists heterogeneity in
compliance and post-mediation treatment effects. More precisely, for each instance value x, we draw
once and for all γ ∈ {0.01, 0.005} and β ∈ {−1, 1, 3, 5, 7} uniformly and independently. Associated
outcome is computed according to the synthetic dataset equation (10). We study four methods: regular
two-models (IPE2M), shared data representation (IPESDR) and their variants, obtained by adding the
intermediate variable M (resp. C− IPE2M, and C− IPESDR). We focus on AUUC metric because
real-world application cannot access individual treatment effect ground truth. Recall that AUUC
measures the capacity of the model to rank individuals according to their IPE . In order to make
sure that learned models perform better than random, we substract the AUUC of a random model,
obtaining ∆AUUC. Finally to scale the performance of the latter models, we report in Figure 4 results
for an Oracle model that has access to the drawn (β, γ), and for IPEbest, the best possible learnt model
without exploiting the observable compliance M (it predicts for each x its empirical IPE average based
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on the training set). Again, variance is estimated by repeating experiment with 51 random test/train
splits.
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Figure 4: Baseline Experiment (Simulation). ∆AUUC (higher is better) of two IPE models,
corresponding C-IPE models and Oracle model (theoretical truth). Box plots are done on 51 random
splits, whiskers at 5/95 percentiles. Note how C-IPE systematically increases AUUC of base estimators.
Figure 4 assesses the performance of C-IPE estimators versus IPE , using the ∆AUUC metric. They
yield a higher ∆AUUC in more than 90% of the random splits. Moreover C-IPE estimators are close to
the Oracle (best model possible) as the Oracle does not significantly outperform them, note that even
the Oracle can misrank users because the validation set is noisy and empirical IPEs do not always follow
the expected ranking. Besides, Figure 4 does not show any limitation of the 2M and SDR models, but
rather highlight the ineffectiveness of such direct IPE estimators if a low compliance is observed. This
phenomenon can be improved by our post-mediation approach thanks to the higher signal of the causal
effect of M on Y . Of course, this synthetic data encodes a simpler setting than real-world data, but
the fact that our proposed post-mediation approach performs that high still confirms our theoretical
analysis.
Real-world Experiment (CRITEO-UPLIFT1)
To qualify the benefit of C-IPE versus IPE for real-world applications we report ∆AUUC on the
CRITEO-UPLIFT1 dataset. We study four methods: two IPE models (IPE2M, and IPESDR) and their
C-IPE variants (resp. C− IPE2M, and C− IPESDR). For the additional γˆ(x) model, care is taken
to weight the LLH as there is a high imbalance between M = 1 and M = 0 classes. We use as an
hyper-parameter grid the Cartesian product of {L1, L2} (regularization) and {0.01, 1, 102, 105} (C,
inverse of regularization strength) for γˆ(x). Best hyper-parameters found are L1 regularization and
C = 100. Results are presented on Figure 5.
The C-IPE version of each models reduces the variance of the ∆AUUC estimate. This was expected
and somehow justified in Proposition 3. Moreover, although the confidence intervals are slightly
superposed, C-IPE always outperforms its IPE counterpart on the 51 splits.
Real-world Experiment (Private Datasets)
For the private datasets, we repeat the same procedure and compare the same metrics. Figure 6
illustrates the differences in ∆AUUC of the learned models and a random model on 33 bootstraps.
The C-IPE models performs better than the two IPE models by having an AUUC significantly better
than the random model, when the two IPE models do not perform better than the random model.
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Figure 5: Real-world Experiment (CRITEO-UPLIFT1). ∆AUUC (higher is better) on test for
two IPE models and corresponding C-IPE models. Box plots computed on 51 random splits, whiskers
at 5/95 percentiles. Note the higher ∆AUUC and reduced variance of C-IPE models.
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Figure 6: Real-world Experiment (Private Datasets). AUUC (higher is better) of two IPE models
and one C-IPE model (based on two models) from which we subtracted the AUUC of a random model.
Box plots are done on 33 bootstraps, whiskers at 5/95 percentiles.
An interesting finding of this experiment is that, in practice, the mild expected benefit of C-IPE,
predicted by the theory (because of a higher compliance than in CRITEO-UPLIFT1 dataset) does not
seem discernible. This is however only an indication as there are multiple differences between the two
datasets that might explain such a behavior.
6 Conclusion and Future Works
We propose a novel approach on individual prescription effect (IPE ) estimation exploiting observed
compliance to the treatment prescription.
Using the structural causal model framework, we define assumptions under which the IPE can be
expressed as a product of the individual treatment effect (ITE) and the individual level of compliance.
In this setting, our post-mediation individual treatment effect (C-IPE) estimator is consistent. Moreover
its asymptotic variance improves with the level of compliance. Experimentally, we show how the
performance of several baseline IPE estimators improve when plugged in the C-IPE meta-estimator.
We also observe the relationship between performance and compliance as predicted by our theoretical
results.
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Finally, this work opens several perspectives among which: i) stability of our results under variations of
assumptions, ii) bound tightness and properties in high-dimensional contexts, and iii) exploration of
how representation learning approaches may uncover by themselves C-IPE-like estimator decomposition
under weaker causal assumptions.
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A Proofs
To ensure a comfortable appendix read we quickly remind, for each lemma and proposition, vocabulary
and notations introduced in the paper that are used in the associated proofs.
A.1 Proposition 1
The structural causal model C = (S,PN) is assumed to represent the causal mechanisms underlying the
variables of interest in our work.
S is defined in Equations (2), and PN satisfies the following mild conditions: NU , NX , NM , NY are
noise consistent with variables definitions, and N˜T is distributed according to a Bernoulli distribution
with parameter p = PC(T ), consistent with a randomized controlled experiment setting.
In Proposition 1, we list four assumptions implied by the C about the variables of interest.
Proof.
The proof of Proposition 1 relies on the notions of valid adjustment set (definition 6.38 of Peters et al.
(2017)), its relation to the back-door criterion (Proposition 6.41 of Peters et al. (2017)), the notion
of d-separation (Definition 6.1 of Peters et al. (2017)) and the Markov property (Proposition 6.21 of
Peters et al. (2017)).
First of all, the SCM C is Markovian with respect to its own entailed distribution (Proposition 6.31 of
Peters et al. (2017)): this implies that every conditional independence encoded (as a d-separation) in
the graph GC holds in distribution PC.
Randomized treatment , is implied by the Markov property and the fact that T and X are
d-separated by the empty set in GC: all paths between T and X contain either → M ← or → Y ←,
which are blocked by not including neither M nor Y .
Exclusive treatment effect is implied by the Markov property and the fact that the set {X,M}
d-separates T and Y in GC. This is shown by listing all paths between T and Y and observing that
they are all blocked by the set {X,M}.
One-sided non-compliance is straightforwardly implied by the structural assignment of M given in
Equations (2).
Valid covariate adjustment relies on the back-door criterion for valid adjustment sets. We remark
that {X} satisfies the back-door criterion for (M ,Y ) because (i) it is not a descendant of M and (ii) it
blocks all paths from M to Y that enter Y through the backdoor: it is therefore a valid adjustment set
for the ordered pair (M,Y ).

A.2 Lemma 1
The proposed method exploits the mediation variable M , i.e. the treatment acceptation, by splitting
the treatment to outcome path into a product of two subpaths, both with a higher noise-to-signal ratio.
In particular, based on the causal graphical model 1, we can integrate M into the PC;do(T )(Y |x) as
presented in Lemma 1.
Proof.
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Assuming the SCM C truly describes the relationships between T,X,M, Y , we have:
PC;do(T )(Y |x) = PC;do(T )(Y,M |x) + PC;do(T )(Y,M |x)
= PC;do(T )(Y |x,M)︸ ︷︷ ︸
PC(Y |x,M)
PC;do(T )(M |x) + PC;do(T )(Y |x,M)︸ ︷︷ ︸
PC(Y |x,M)
PC;do(T )(M |x)
= PC(Y |x,M)PC;do(T )(M |x) + PC(Y |x,M)PC;do(T )(M |x)
= PC(Y |x,M)PC;do(T )(M |x) + PC(Y |x,M)PC;do(T )(M |x)︸ ︷︷ ︸
1−PC;do(T )(M |x)
= PC(M |x, T )
(
PC(Y |x,M)− PC(Y |x,M)
)
+ PC(Y |x,M),
where we used assumptions described Equation 3, namely:
• PC;do(M)(Y |x) = PC(Y |M,x) (Valid covariate adjustment),
• PC;do(T )(·|x, ·) = PC(·|x, T, ·) (Randomized treatment),
• PC(Y |x, T,M) = PC(Y |x,M) (Exclusive treatment effect),
and the claim follows. 
A.3 Proposition 2
For all x ∈ X , we define the individual treatment effect τ IPE(x), treatment effect if treated τ ITE(x), as
well as the individual compliance γ(x) probability (that we henceforth refer to as individual compliance
for clarity) in Equations (4).
In Proposition 2, we propose a result linking the IPE , the ITE and the compliance probability,
namely
τ IPE(x) = τ ITE(x)γ(x).
Proof
We have an analogous version of (5) for the term PC;do(T )(Y |x):
PC;do(T )(Y |x) = PC(Y |x,M) + PC(M |x, T )
(
PC(Y |x,M)− PC(Y |x,M)
)
.
Since T ⇒ M (One-sided non-compliance assumption), we get that, ∀x ∈ X , PC(M |x, T ) = 0, and
finally:
PC;do(T )(Y |x) = PC(Y |x,M).
Then:
τ IPE(x) = PC;do(T )(Y |x)− PC;do(T )(Y |x)
= PC(M |x, T )
(
PC(Y |x,M)− PC(Y |x,M)
)
+ PC(Y |x,M)− PC(Y |x, T )︸ ︷︷ ︸
PC(Y |x,M)
= PC(M |x, T )
(
PC(Y |x,M)− PC(Y |x,M)
)
.
which completes the proof.

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A.4 Proposition 3
Single-stratum setting. We focus on the IPE estimation for a single value x0 of X, for which we
assume to observe n i.i.d. samples {(x0, Ti,Mi, Yi)}1≤i≤n.
Notations. Consistently with notations presented in Equations 4, α(x0), β(x0) refer respectively
to the relative IPE and relative ITE in stratum {X = x0} (and are assumed to be positive in this
illustrative setting), and we denote γˆ(x0), τˆ
IPE(x0) and τˆ
ITE(x0) respectively the maximum-likelihood
estimator (MLE) of γ(x0), and the MLE-based two-model estimators (difference of two MLE estimators)
of τ IPE(x0) and τ
ITE(x0). We define the associated C-IPE estimator as τˆ
C−IPE(x0) , γˆ(x0)τˆ ITE(x0).
Lastly, we denote p1(x0) = PC(Y |T, x0).
In Proposition 3, we present an asymptotic bound for the ratio of the standard deviation (sd) of
C-IPE and IPE estimators (additionally assuming PC(T ) = 12 for simplicity), namely:
lim
n→∞
sd(τˆC−IPE(x0))
sd(τˆ IPE(x0))
≤
√(
2(1 + β(x0))
(1− p1(x0))(2 + α(x0))
)
γ(x0)
Proof.
The proof is splitted in four steps:
1. Maximum-Likelihood and treatment effect estimators
2. Variance of estimators derivation
3. Variance upper and lower bounds
4. Wrap up
Every random quantity is henceforth implicitly considered to be ‘with respect to x0’.
1. Maximum-Likelihood and treatment effect estimators We remind that for two categorical
random variables X and Y , for which we observe n i.i.d. samples {(Xi, Yi)}1≤i≤n, we have the
following Maximum-Likelihood estimators for p(x) = P (X = x), p(x, y) = P (X = x, Y = y) and
p(y|x) = P (X = x|Y = y):
pˆ(x) =
1
n
n∑
i=1
IXi=x
pˆ(x, y) =
1
n
n∑
i=1
IXi=xIYi=y
pˆ(y|x) =
n∑
i=1
IXi=xIYi=y
n∑
i=1
IXi=x
.
(11)
Since
n∑
i=1
IXi=x = 0⇒
n∑
i=1
IXi=xIYi=y = 0, we adopt the convention Pˆ (X = x|Y = y) = 0 in case of null
denominator for a ratio estimator such as pˆ(X = x|Y = y), ensuring they are well defined for any samples.
In our context, we have n i.i.d. samples {(Ti,Mi, Yi)}1≤i≤n of variables (T,M, Y ), and that we
suppose PC(T ) = 12 .
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We first define the following compact notations:
t = PC(T ) γ = PC(M |T )
p0 = PC(Y |T ) p1 = PC(Y |T )
q0 = PC(Y |M) q1 = PC(Y |M)
Associated MLEs pˆ0, pˆ1, qˆ0, qˆ1, tˆ and γˆ are given by Equations (11). For instance:
tˆ =
1
n
n∑
i=1
Ti γˆ =
1
n∑
i=1
Ti
n∑
i=1
Mi
pˆ0 =
1
n∑
i=1
(1− Ti)
n∑
i=1
(1− Ti)Yi pˆ1 = 1n∑
i=1
Ti
n∑
i=1
TiYi
qˆ0 =
1
n∑
i=1
(1−Mi)
n∑
i=1
(1−Mi)Yi qˆ1 = 1n∑
i=1
Mi
n∑
i=1
MiYi
Direct estimators for τ IPE , τ ITE are given by applying the two-model approach to MLEs given in
these equations, i.e.
τˆ IPE = pˆ1 − pˆ0
τˆ ITE = qˆ1 − qˆ0
and the corresponding τC−IPE estimator therefore writes:
τˆC−IPE = (qˆ1 − qˆ0)γˆ.
In what follows, we will now write
∑
i instead of
n∑
i=1
when there is no ambiguity.
2. Variance of estimators derivation
2.a. τˆ IPE variance derivation
For any random variables X,Y , we remind that:
Var(X) = Var(E[X|Y ]) + E[Var(X|Y )]. (12)
Which applied with X = τˆ IPE = pˆ1 − pˆ0 and Y = {Tk}k := {T1, . . . , Tn}, gives:
Var(τˆ IPE) = E
[
Var(τˆ IPE |{Tk}k)
]︸ ︷︷ ︸
A
+ Var
[
E(τˆ IPE |{Tk}k)
]︸ ︷︷ ︸
B
. (13)
Computation of A
The term Var(τˆ IPE |{Tk}k) decomposes as:
Var(τˆ IPE |{Tk}k) = Var(pˆ1|{Tk}k)︸ ︷︷ ︸
A1
+ Var(pˆ0|{Tk}k)︸ ︷︷ ︸
A2
−2 Cov(pˆ1, pˆ0|{Tk}k)︸ ︷︷ ︸
A3
. (14)
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For A1 , we write:
Var(pˆ1|{Tk}k) = Var
(
1∑
i Ti
∑
i
TiYi|{Tk}k
)
=
(
1∑
i Ti
)2
Var
(∑
i
TiYi|{Tk}k
)
=
(
1∑
i Ti
)2∑
i
Var(TiYi| {Tk}k︸ ︷︷ ︸
Ti (since i.i.d.)
)
=
(
1∑
i Ti
)2∑
i
TiVar(Yi|Ti)︸ ︷︷ ︸
Var(Y |T=1)Ti (since i.i.d.)
=
(
1∑
i Ti
)2
Var(Y |T = 1)
∑
i
Ti
=
1∑
i Ti
Var(Y |T = 1)
=
1∑
i Ti
p1(1− p1).
For A2 , we analogously get:
Var(pˆ0|{Tk}k) = 1∑
i(1− Ti)
p0(1− p0).
For A3 , using the bi-linearity of covariance, we write:
Cov (pˆ1, pˆ0|{Tk}k) = Cov
 1∑
i Ti
∑
i
TiYi,
1∑
j(1− Tj)
∑
j
(1− Tj)Yj |{Tk}k

=
1∑
i Ti
1∑
j(1− Tj)
Cov
∑
i
TiYi,
∑
j
(1− Tj)Yj |{Tk}k

=
1∑
i Ti
1∑
j(1− Tj)
∑
i
∑
j
(1− Tj)Ti Cov (Yi, Yj |{Tk}k)︸ ︷︷ ︸
6=0 only if i=j (since i.i.d.)
=
1∑
i Ti
1∑
j(1− Tj)
∑
i
(1− Ti)TiCov(Yi, Yi| {Tk}k︸ ︷︷ ︸
Ti (since i.i.d.)
)
=
1∑
i Ti
1∑
j(1− Tj)
∑
i
(1− Ti)Ti︸ ︷︷ ︸
=0
Var(Yi|Ti)
= 0.
Injecting values of A1 , A2 and A3 in Equation (14) we get:
Var(τˆ IPE |{Tk}k) = 1∑
i Ti
p1(1− p1) + 1∑
i(1− Ti)
p0(1− p0). (15)
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Which leads to the following expression for A :
E
[
Var(τˆ IPE |{Tk}k)
]
= E
[
1∑
i Ti
]
p1(1− p1) + E
[
1∑
i(1− Ti)
]
p0(1− p0). (16)
Computation of B
We may write
E(τˆ IPE |{Tk}k) = E(pˆ1|{Tk}k)︸ ︷︷ ︸
B1
−E(pˆ0|{Tk}k)︸ ︷︷ ︸
B2
.
For B1 , we write:
E(pˆ1|{Tk}k) = E
(
1∑
i Ti
∑
i
TiYi|{Tk}k
)
=
1∑
i Ti
∑
i
E (TiYi|{Tk}k)
=
1∑
i Ti
∑
i
Ti E(Yi|Ti)︸ ︷︷ ︸
p1
=
1∑
i Ti
(∑
i
Ti
)
p1
= p1.
For B2 , we analogously get: E(pˆ0|{Tk}k) = p0.
Therefore E(τˆ IPE |{Tk}k) = p1 − p0 is constant relatively to {Tk}k, and we have computed B :
Var
[
E(τˆ IPE |{Tk}k)
]
= 0. (17)
Combining Equations (13), (16) and (17) we end up with:
Var(τˆ IPE) = E
[
1∑
i Ti
]
p1(1− p1) + E
[
1∑
i(1− Ti)
]
p0(1− p0). (18)
2.b. τˆC−IPE variance derivation
Using Equation (12) with X = τˆC−IPE = γˆ(qˆ1 − qˆ0) and Y = {Tk,Mk}k we may write:
Var(τˆC−IPE) = E
[
Var(τˆC−IPE |{Tk,Mk}k)
]︸ ︷︷ ︸
C
+ Var
[
E(τˆC−IPE |{Tk,Mk}k)
]︸ ︷︷ ︸
D
. (19)
Computation of C
Using the fact that τˆC−IPE = γˆ(qˆ1 − qˆ0), and remarking that E[γˆ|{Tk,Mk}k] = γˆ, we may write:
Var(γˆ(qˆ1 − qˆ0)|{Tk,Mk}k) = γˆ2Var((qˆ1 − qˆ0)|{Tk,Mk}k)
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By analogy with Equation (15), we have
Var(qˆ1 − qˆ0)|{Tk,Mk}k) = 1∑
iMi
q1(1− q1) + 1∑
i(1−Mi)
q0(1− q0),
which gives
Var(γˆ(qˆ1 − qˆ0)|{Tk,Mk}k) = γˆ2( 1∑
iMi
q1(1− q1) + 1∑
i(1−Mi)
q0(1− q0)). (20)
Injecting γˆ =
∑
iMi∑
i Ti
=
∑
iMiTi∑
i Ti
in (20), we get:
Var(γˆ(qˆ1 − qˆ0)|{Tk,Mk}k) =
∑
iMi
(
∑
i Ti)
2 q1(1− q1) +
(
∑
iMi)
2
(
∑
i Ti)
2∑
i(1−Mi)
q0(1− q0).
Taking the expectancy, we therefore get the following expression for C :
E
[
Var(τˆC−IPE |{Tk,Mk}k)
]
= E
[ ∑
iMi
(
∑
i Ti)
2
]
q1(1− q1) + E
[
(
∑
iMi)
2
(
∑
i Ti)
2∑
i(1−Mi)
]
q0(1− q0). (21)
Computation of D
Using the fact that γˆ is {Tk,Mk}k−measurable, we get:
E(τˆC−IPE |{Tk,Mk}k) = γˆ(E(qˆ1|{Tk,Mk}k)︸ ︷︷ ︸
D1
−E(qˆ0|{Tk,Mk}k)︸ ︷︷ ︸
D2
). (22)
For D1 , a few mechanical computations bring:
E(qˆ1|{Tk,Mk}k) = E
(
1∑
iMi
∑
i
MiYi|{Tk,Mk}k
)
=
1∑
iMi
E
(∑
i
MiYi|{Tk,Mk}k
)
=
1∑
iMi
∑
i
MiE (Yi|{Tk,Mk}k)
=
1∑
iMi
∑
i
MiE (Yi|Ti,Mi)︸ ︷︷ ︸
MiE[Y |M=1]
= E[Y |M = 1]︸ ︷︷ ︸
q1
1∑
iMi
∑
i
Mi
= q1
For D2 , we analogously get:
E(qˆ0|{Tk,Mk}k) = q0.
Injecting these values in (22):
E(τˆC−IPE |{Tk,Mk}k) = γˆ(q1 − q0).
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which gives the following expression for D :
Var
(
E(τˆC−IPE |{Tk,Mk}k)
)
= (q1 − q0)2Var(γˆ).
Using the fact that Var(γˆ) = E(Var(γˆ|{Tk})) + Var(E[γˆ|{Tk}]), we get:
Var(γˆ) = E
(
1∑
i Ti
)
γ(1− γ).
We end up with the final expression for D :
Var
(
E
[
τˆC−IPE |{Tk,Mk}k
])
= (q1 − q0)2E
[
1∑
i Ti
]
γ(1− γ). (23)
Combining Equations (19), (21) and (23), we have:
Var(τˆC−IPE) = E
[ ∑
iMi
(
∑
i Ti)
2
]
q1(1−q1)+E
[
(
∑
iMi)
2
(
∑
i Ti)
2∑
i(1−Mi)
]
q0(1−q0)+(q1−q0)2E
(
1∑
i Ti
)
γ(1−γ).
(24)
3. Asymptotic variance upper and lower bounds
3.a Asymptotic lower bound of Var(τˆ IPE) With a slight rewriting of (18),
nVar(τˆ IPE) = E
[
1
1
n
∑
i Ti
]
p1(1− p1) + E
[
1
1
n
∑
i(1− Ti)
]
p0(1− p0).
Then because t = PC(T ) = 12 , by the law of large numbers , we get
lim
n→∞nVar(τˆ
IPE) = 2 (p1(1− p1) + p0(1− p0)) . (25)
Now, using p1 = (1 + α)p0, we can write:
lim
n→∞nVar(τˆ
IPE) = 2p0 (1− p0 + (1 + α)(1− p1))
≥ 2p0 (1− p1 + (1 + α)(1− p1))
= 2p0(1− p1)(2 + α),
where the first inequality uses α ≥ 0. In summary, we have the following asymptotic lower bound for
Var(τˆ IPE):
lim
n→∞nVar(τˆ
IPE) ≥ 2p0(1− p1)(2 + α). (26)
3.a Asymptotic upper bound of Var(τˆC−IPE)
From (24), we have
nVar(τˆC−IPE) = E
[
1
n
∑
iMi(
1
n
∑
i Ti
)2
]
q1(1− q1) + E
[ (
1
n
∑
iMi
)2(
1
n
∑
i Ti
)2 1
n
∑
i(1−Mi)
]
q0(1− q0)
+ (q1 − q0)2E
(
1
1
n
∑
i Ti
)
γ(1− γ). (27)
Again, using the law of large numbers , we get
lim
n→∞nVar(τˆ
C−IPE) = 2γq1(1− q1) + 2 γ
2
2− γ q0(1− q0) + 2γ(1− γ)(q1 − q0)
2. (28)
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Now, using that for any q ∈ [0, 1], q(1− q) ≤ q, and reminding that q1 = (1 + β)q0 ≤ 1 where β ≥ 0 by
assumption, we get:
lim
n→∞nVar(τˆ
C−IPE) = 2γq1(1− q1) + 2 γ
2
2− γ q0(1− q0) + 2γ(1− γ)(q1 − q0)
≤ 2γ
 q1︸︷︷︸
βq0
+
γ
2− γ︸ ︷︷ ︸
≤γ≤1
q0 + (q0(1 + β))
2︸ ︷︷ ︸
≤q0(1+β)

≤ 2γq0 (1 + β + 1 + β)
= 4q0γ(1 + β).
In summary, we have the following asymptotic upper bound for Var(τˆC−IPE):
lim
n→∞nVar(τˆ
C−IPE) ≤ 4q0γ(1 + β). (29)
4. Wrap up
Combining Equations (26) and (29) (ratio of positive values), we get
lim
n→∞nVar(τˆ
C−IPE)
lim
n→∞nVar(τˆ
IPE)
≤ 4q0γ(1 + β)
2p0(1− p1)(2 + α)
= 2
1 + β
(1− p1)(2 + α)γ.
Where we remind that One-sided non-compliance and Exclusive treatment effect imply straightforwardly
that p0 = q0 (as shown in the beginning of the proof of Proposition 2). Since the limits of both the
numerator and denominator exist, this implies that
lim
n→∞
Var(τˆC−IPE)
Var(τˆ IPE)
≤ 2 1 + β
(1− p1)(2 + α)γ.
Taking the square root of this equation gives the wanted result.

B Additional Results and Experimentation Details
B.1 AUUC
AUUC (Rzepakowski & Jaroszewicz, 2012, 2010; Radcliffe & Surry, 2011) is the Area Under the Uplift
Curve. It is obtained by ranking the users of a test set according to their predicted uplift, in descending
order.
The uplift curve starts at the point (0, 0), then for each user (in decreasing order of the predicted
uplift) it goes up of 1 point if the user is in group T = 1 with Y = 1, it goes down of 1 point if the user
is in group T = 0 with Y = 1, and it stays flat if the user has Y = 0. So the label l is Y ∗ (2T − 1). We
normalise the x-axis so that it goes from 0 to 1.
The aim of uplift model is to rank first the users with positive outcome in treatment (T = 1), then
the users with negative outcome, and finally the users with positive outcome not in treatment (T = 0).
Thus, the area under the uplift curve is maximal.
However the value of the AUUC highly depends on the test set. Indeed the first point of the uplift
curve is always (0, 0) and the last one is always (1, U) were U =
∑
Y T −∑Y (1− T ). Therefore the
variability of the test set (when we do different splits) accounts for part of the variability of the metrics.
To reduce this variability, we subtract the average AUUC of a random model (which is equal to U2 )
from the AUUC of tested models. This measure is called ∆AUUC.
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uˆl cumul
10
5
Figure 7: Example of uplift curves. The blue line corresponds to a perfect model, the green line is the
expectation of a random model and the red line is an example of a model. The AUUC is the area under
those curves.
B.2 Models training
Our goal is to compare the IPE (Individual Treatment Effect) approach with C-IPE (post-Mediation
Individual Treatment Effect) approach. We implement two kinds of model for both IPE and ITE (In-
dividual Treatment Effect if Treated) factor of C-IPE. These models are (1) the Two-Models, with
one model learnt on the group T = 1 and one model learnt on the group T = 0, and (2) Shared Data
Representation (SDR), from Betlei et al. (2018), which is inspired from multi-task learning and has
more capacity than the basic Two-Models approach.
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Figure 8: ∆AUUC (higher is better) of two IPE models, corresponding C-IPE models and Oracle model
(theoretical truth). Box plots are done on 51 random splits, whiskers at 5/95 percentiles. Note how
C-IPE systematically increases AUUC of base estimators
On synthetic data, we also compare the models to two theoretical models: IPEbest and Oracle:
• IPEbest is the best possible model learn-able using training data but without exploiting information
from the mediation variable M . In short, this model predicts the difference of the empirical
positive outcome rate in the group T = 1 and in the group T = 0 and does so in each category of
users. This is a rightful approach in the case of our synthetic dataset, since we observe a high
number of users for each possible category (each value of x). It is the best possible model learnt,
because the dataset is generated with one different probability of positive outcome per category:
there is nothing else any model could learn without exploiting variable M .
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IPEbest allows us to show that, in our synthetic dataset, two models and SDR perform close to the
best possible IPE approach. In that specific low-dimensional case, there is therefore no need to
implement more complex models (Figure 8) such as doubly-robust methods or tree/forest-based
methods.
• Oracle predicts the theoretical ground truth uplift (used to generate the dataset). Its score is
important since it represents the maximum theoretically reachable score (on average). In practice,
we observe that it is however not the best model on all random splits. This can be explained by
the fact that the (test) dataset is randomly generated, and that the ranking of users in the test
set can therefore differ slightly from the theoretical ranking.
All learnt models (IPE, C-IPE and IPEbest) suffer from the randomness of the training dataset.
B.3 Models testing
In addition of the randomness of the training dataset, the test dataset is also random. This adds
noise to the AUUC values that are computed in practice. We design a metric called, AUUCthout that
computes the AUUC on a theoretical test set. This metric may only be implemented on synthetic data.
It uses the ”Theoretical Outcome” (thout) of each category of users as a label, thus circumventing the
randomness inherent to the test set generation.
Figure 9 represents the performance of the same models as in Figure 8 but with the AUUCthout
metric (AUUC on a theoretical test set). As expected the Oracle has no variance because it does not
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Figure 9: ∆AUUCthout (higher is better) of two IPE models, corresponding C-IPE models and Oracle
model (theoretical truth). Box plots are done on 51 random splits, whiskers at 5/95 percentiles. Note
how C-IPE systematically increases AUUC of base estimators
suffer from the randomness of the training set (by design) and the AUUCthout metric gets rid of the
variance of the test set. C-IPE models also have little to no AUUCthout variance in practice. This can
be explained by the fact that these models learn the post mediation (ITE ) signal, which is far less
noisy than the IPE signal in low-compliance cases, and therefore suffer from less random variation.
B.4 Hyper-parameters tuning
For the open dataset CRITEO-UPLIFT12, we first fit the compliance model γˆ(x) estimating the true
individual compliance γ(x) = PC;do(T )(M |x) probability, from a separate process. Specifically, γˆ(x)
2http://cail.criteo.com/criteo-uplift-prediction-dataset/
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model is fitted directly as we have access to the compliance label M . We use a rebalanced LLH, as the
classes M = 1 and M = 0 are very imbalanced. This step is crucial, as a good γˆ model ensures the
superiority of C-IPE-based algorithms. The models are implemented using the logistic regression class,
from Scikit-Learn Python library Pedregosa et al. (2011). We use for the hyper-parameter grid the
Cartesian product of:
Table 4: Table of hyper-parameters for the compliance model
parameter values
penalty regularization {L1, L2}
C: inverse of regularization strength {0.01, 1, 102, 105}
class weight: weights associated with classes {balanced,None}
Hyper-parameters are selected by internal 11-fold cross-validation on the training set by ranking by
rebalanced log-likelihood as the model is predicting a probability. The best hyper-parameter triple
found is L1 regularization, C = 100 and class weight = ’balanced’.
In a second step, we tune the two individual treatment effect models τˆ IPE and τˆ ITE , by doing
again an internal cross-validation on the training set. We rank the hyper-parameters configuration by
the delta AUUC metric, computed averaging over the different splits. The hyper-parameters grid is the
Cartesian product of:
Table 5: Table of hyper-parameters for the individual treatment effect models
parameter values
penalty regularization {L1, L2}
C: inverse of regularization strength {0.01, 0.1, 1, 10, 102, 103, 104, 105}
Remark: for the plot of Figure 5, we only show the penalization L2, with an inverse regularization
strength C = 10 as the ∆AUUC is found not sensitive to hyper-parameter (see subscript COMP in
Table 6). Indeed the best hyper-parameters tuple (see subscript BEST in Table 6) for each method are
the following:
Table 6: Table of hyper-parameters for the models. The metric is ∆AUUC
method Cbest penaltybest ∆AUUCbest Ccomp penaltycomp ∆AUUCcomp
IPE2M 100000.0 L1 20484.044762 10.0 L2 20249.085940
IPESDR 1.0 L1 20596.476241 10.0 L2 20179.615970
C− IPE2M 10.0 L2 21507.813960 10.0 L2 21507.813960
C− IPESDR 1.0 L2 21454.981632 10.0 L2 21333.441887
The corresponding performance the the best configuration are presented in Figure 10. Note that
the order of magnitude for each method is very similar with the Figure 5, i.e. for penalization L2 and
C = 10, which makes the fine tuning of the hyper-parameters unnecessary.
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Figure 10: ∆AUUC (higher is better) for the best hyper-parameter configurations. Box plots are done
on 100 random splits, whiskers at 5/95 percentiles. Note how C-IPE systematically increases ∆AUUC
of IPE estimators
C Code
The full code used for (1) the experiments on synthetic data and (2) experiments on real-world open
data described in this paper can be found in the experiment src.zip file. The unzipped folder contains
a README.md file that gives precise instructions enabling to re-run all experiments, and compare the
results with the corresponding ones in the paper.
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